Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study

BackgroundPreclinical studies demonstrated that immune checkpoint inhibitors combined with antiangiogenic drugs have a synergistic anti-tumor effect. This present phase II trial aimed to evaluate the efficacy and safety of apatinib combined with camrelizumab in patients with recurrent/metastatic nas...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yunyan Mo, Yufei Pan, Bin Zhang, Jian Zhang, Yixin Su, Zhengchun Liu, Meiqing Luo, Guanjie Qin, Xiangyun Kong, Rongjun Zhang, Yu Pan, Yi Liang, Defeng Wang, Yuejia Wei, Hengwei Chen, Wei Jiang
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2024-01-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	nasopharyngeal carcinoma clinical trial immunotherapy targeted therapy apatinib camrelizumab
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1298418/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!